Cargando…

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report

BACKGROUND: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk. METHODS: Approval for rapid exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Chris, Tipton, Tom, Sabir, Suleman, Aitken, Celia, Bennett, Susan, Becker, Stephan, Evans, Tom, Fehling, Sarah Katharina, Gunson, Rory, Hall, Yper, Jackson, Celia, Johanssen, Ingolfur, Kieny, Marie Paule, Mcmenamin, Jim, Spence, Elizabeth, Strecker, Thomas, Sykes, Catie, Templeton, Kate, Thorburn, Fiona, Peters, Erica, Henao Restrepo, Ana Maria, White, Beth, Zambon, Maria, Carroll, Miles W, Thomson, Emma C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778350/ https://www.ncbi.nlm.nih.gov/pubmed/31784751 http://dx.doi.org/10.1093/cid/ciz1165

Ejemplares similares

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
por: Cross, Robert W., et al.
Publicado: (2020)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013–2016 West Africa Ebola outbreak in Guinea
por: Boum, Yap, et al.
Publicado: (2020)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Author Correction: Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
por: Vianello, Eleonora, et al.
Publicado: (2022)

Titration methods for rVSV-based vaccine manufacturing
por: Gélinas, Jean-François, et al.
Publicado: (2020)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
por: Legardy-Williams, Jennifer K., et al.
Publicado: (2020)

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines
por: Coller, Beth-Ann G., et al.
Publicado: (2022)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
por: Kainulainen, Markus H., et al.
Publicado: (2023)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
por: Schwartz, David A.
Publicado: (2020)

Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
por: Halperin, Scott A, et al.
Publicado: (2019)

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures
por: Kiesslich, Sascha, et al.
Publicado: (2021)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
por: Monath, Thomas P., et al.
Publicado: (2019)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

28. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO™) in Participants by Age, Sex, and Baseline GP-ELISA Titer: A Post Hoc Analysis of Three Phase 2/3 Trials
por: Simon, Jakub, et al.
Publicado: (2020)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
por: Cao, Wenguang, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
por: Yahalom-Ronen, Yfat, et al.
Publicado: (2022)

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine
por: Yang, Zeyu, et al.
Publicado: (2023)

Transcriptomic analysis reveals a previously unknown role for CD8(+) T-cells in rVSV-EBOV mediated protection
por: Menicucci, Andrea R., et al.
Publicado: (2017)

Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
por: Ton, Christopher, et al.
Publicado: (2023)

Single dose of a rVSV-based vaccine elicits complete protection against severe fever with thrombocytopenia syndrome virus
por: Dong, Fangfang, et al.
Publicado: (2019)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
por: Sorvillo, Teresa E., et al.
Publicado: (2021)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
por: Henao-Restrepo, Ana Maria, et al.
Publicado: (2017)

Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
por: Makovitzki, Arik, et al.
Publicado: (2021)

Preliminary nonclinical safety and immunogenicity of an rVSV-ΔG-SARS-CoV-2-S vaccine in mice, hamsters, rabbits and pigs
por: Madar-Balakirski, Noa, et al.
Publicado: (2022)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
por: Gillespie, Paul F., et al.
Publicado: (2023)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
por: Fuchs, JD, et al.
Publicado: (2012)

Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus
por: Ding, Limin S., et al.
Publicado: (2022)

Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies
por: Steeds, Kimberley, et al.
Publicado: (2020)

Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV-ΔG-Spike Vaccination Efficacy
por: Melamed, Sharon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oh7hsg4fh0na4k0u7qkjg6h6nj